2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:76

Article

Das, Sandeep R.¹  Everett, Brendan M.²  Birtcher, Kim K.³  Brown, Jenifer M.⁴  Januzzi, James L., Jr.⁵  Kalyani, Rita R.⁶  Kosiborod, Mikhail^7,8  Magwire, Melissa⁹  Morris, Pamela B.^10,11  Neumiller, Joshua J.^12,13  Sperling, Laurence S.^14,15,16 

[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA

[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[3] Univ Houston, Coll Pharm, Houston, TX 77004 USA

[4] Brigham & Womens Hosp, Cardiol, Boston, MA 02115 USA

[5] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA 02115 USA

[6] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21218 USA

[7] St Lukes Mid Amer Heart Inst, Kansas City, MO USA

[8] Univ Missouri Kansas City, Med, Kansas City, MO USA

[9] St Lukes Hlth Syst, Cardiometabol Ctr Alliance, Kansas City, MO USA

[10] Med Univ South Carolina, Seinsheimer Cardiovasc Hlth Program, Columbia, SC USA

[11] Med Univ South Carolina, Womens Heart Care, Columbia, SC USA

[12] Washington State Univ, Pullman, WA 99164 USA

[13] Washington State Univ, Pharmacotherapy, Pullman, WA 99164 USA

[14] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA

[15] Emory Univ, Atlanta, GA 30322 USA

[16] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Global Hlth, Atlanta, GA 30322 USA

关键词: ACC Expert Consensus Decision Pathway;    atherosclerotic cardiovascular disease;    cardiovascular risk reduction;    diabetes;    GLP-1RA;    SGLT2 inhibitor;    type 2 diabetes;   

DOI  :  10.1016/j.jacc.2020.05.037

来源: Elsevier

【 授权许可】

Free